Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM-IL-12 with Low Dose TSEBT in CTCL
NCT02542124Phase 2Unknown
- Sponsor
- Neumedicines Inc.
- Start
- Dec 2015
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of HemaMax in cutaneous T-cell lymphoma (CTCL), sponsored by Neumedicines Inc.. Status: unknown.
02
Drugs
HemaMax
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02542124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542124.